Seladelpar
chemical compound
Seladelpar, sold under the brand name Livdelzi, is a medication used for the treatment of primary biliary cholangitis. It is used as the lysine dihydrate salt. It is a peroxisome proliferator-activated receptor delta (PPARδ) receptor agonist. The compound was licensed from Janssen Pharmaceutica NV.
Seladelpar was approved for medical use in the United States in August 2024.
Medical uses
Seladelpar is indicated for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults who have an inadequate response to ursodeoxycholic acid, or as monotherapy in people unable to tolerate ursodeoxycholic acid.
Clinically, seladelpar reduces pruritus (itching) and interleukin-31 in people with primary biliary cholangitis.
Society and culture
Legal status
Seladelpar was approved for medical use in the United States in August 2024. The FDA granted the application breakthrough therapy designation.
In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Seladelpar Gilead, intended for the treatment of primary biliary cholangitis. The applicant for this medicinal product is Gilead Sciences Ireland UC. Seladelpar was authorized for medical use in the European Union in February 2025.
The public source identifies “Seladelpar” as chemical compound. This brief keeps that definition visible, then builds a research path around Seladelpar, chemical and compound.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Seladelpar”, the useful work is to connect “chemical compound” to the records capable of establishing context and consequence.
The date and method of observation matter as much as the stated conclusion, especially where classification or consensus has changed. The source revision retrieved here is dated Aug 21, 2026. The linked authority identifier is Q27268037. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2024 and 2025.
Current terminology should not be projected backward without checking the classification used when the underlying evidence was created. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Seladelpar”, its source revision and the description used here.
- Expand the search: follow Seladelpar primary sources, Seladelpar archive and Seladelpar research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Seladelpar”?
- Which observation, specimen, dataset or publication supports the account?
- Has classification or technical consensus changed since the cited source?
Search terms from this dossier
This entry incorporates text from “Seladelpar” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.